TARSUS PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
TARSUS PHARMACEUTICALS, INC. (TARS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements of $24.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements · last filed 2024-05-08
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2024-03-31 was $24.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 3 month |
|---|---|
| 2024-03-31 | $24.00K 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |